USANA Health Sciences (NYSE:USNA) Announces Earnings Results, Beats Estimates By $0.19 EPS

USANA Health Sciences (NYSE:USNA) released its quarterly earnings results on Tuesday. The company reported $0.60 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.19, Zacks reports. USANA Health Sciences had a return on equity of 6.97% and a net margin of 1.86%.

USANA Health Sciences Stock Down 1.4%

Shares of USNA stock traded down $0.29 during trading hours on Tuesday, hitting $20.61. 103,603 shares of the company’s stock traded hands, compared to its average volume of 113,000. The stock’s fifty day simple moving average is $20.71 and its two-hundred day simple moving average is $23.69. USANA Health Sciences has a 12-month low of $18.48 and a 12-month high of $38.32. The stock has a market cap of $376.75 million, a price-to-earnings ratio of 23.42, a PEG ratio of 0.95 and a beta of 0.67.

Hedge Funds Weigh In On USANA Health Sciences

A number of hedge funds have recently bought and sold shares of the company. Russell Investments Group Ltd. increased its position in shares of USANA Health Sciences by 4.6% during the fourth quarter. Russell Investments Group Ltd. now owns 12,431 shares of the company’s stock valued at $244,000 after acquiring an additional 542 shares in the last quarter. ExodusPoint Capital Management LP boosted its stake in USANA Health Sciences by 58.4% during the 4th quarter. ExodusPoint Capital Management LP now owns 28,625 shares of the company’s stock valued at $562,000 after purchasing an additional 10,552 shares during the last quarter. Barclays PLC increased its holdings in shares of USANA Health Sciences by 57.9% in the 4th quarter. Barclays PLC now owns 49,271 shares of the company’s stock worth $967,000 after purchasing an additional 18,068 shares in the last quarter. Nantahala Capital Management LLC purchased a new stake in shares of USANA Health Sciences during the fourth quarter valued at $11,485,000. Finally, First Trust Advisors LP bought a new stake in USANA Health Sciences in the 4th quarter worth about $246,000. Institutional investors own 54.25% of the company’s stock.

Analyst Ratings Changes

USNA has been the subject of several research reports. Zacks Research lowered shares of USANA Health Sciences from a “hold” rating to a “strong sell” rating in a report on Wednesday, January 7th. Weiss Ratings reiterated a “sell (d)” rating on shares of USANA Health Sciences in a research report on Monday, December 29th. Two analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, USANA Health Sciences presently has an average rating of “Reduce” and an average price target of $36.00.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.